Suda Pharmaceuticals LTD (Asx: Sud)

suda pharmaceuticals ltd engages in the development of drug delivery technology in australia, india, europe and korea. it offers zolpimist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of ambien or stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. the company's product pipeline includes sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. suda pharmaceuticals ltd has license and supply agreement with teva pharmaceuticals international gmbh and mitsubishi tanabe pharma singapore for zolpimist oral spray; product development, licence, and supply agreement with cann pharmaceutical australia ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreem